ArticleAmerican journal of clinical oncology2018

Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab.

Ruby F Meredith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.